Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Raderer M
Authors: Raderer M, Hörsch D, Lahner H, Rinke A, Denecke T,
Keywords: GEP-NET, Lanreotide, Temozolomide,
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Singh S
Authors: Singh S, Carnaghi C, Buzzoni R, Raderer M, Lahner H,
Keywords: Everolimus, progression-free survival, gastrointestinal NET,
Introduction: Little is known about optimal 2nd-line treatment in patients with GI-NEC failing cisplatin-based therapy.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Kiesewetter B, Koparek O, Mayerhoefer M, Niederle B, Raderer M,
Keywords: GI-NEC,
Introduction: The CLARINET study showed LAN 120 mg prolonged PFS vs. placebo (PBO) in patients with metastatic EP-NETs.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,
Keywords: lanreotide, biomarker,
Introduction: In CLARINET, favourable efficacy and safety with LAN in metastatic EP-NETs was associated with stable HRQoL outcomes.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,
Keywords: lanreotide, quality of life,